Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CLS HOLDINGS USA, INC.

(CLSH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

CLS USA : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)

10/12/2021 | 07:03am EST

HISTORY AND OUTLOOK




We were incorporated on March 31, 2011 as Adelt Design, Inc. to manufacture and
market carpet binding art. Production and marketing of carpet binding art never
commenced. On November 20, 2014, we adopted amended and restated articles of
incorporation, thereby changing our name to CLS Holdings USA, Inc. Effective
December 10, 2014, we effected a reverse stock split of our issued and
outstanding common stock at a ratio of 1-for-0.625 (the "Reverse Split"),
wherein 0.625 shares of our common stock were issued in exchange for each share
of common stock issued and outstanding.



On April 29, 2015, the Company, CLS Labs and the Merger Sub consummated the Merger, whereby the Merger Sub merged with and into CLS Labs, with CLS Labs remaining as the surviving entity. As a result of the Merger, we acquired the business of CLS Labs and abandoned our previous business. As such, only the financial statements of CLS Labs are included herein.




CLS Labs was originally incorporated in the state of Nevada on May 1, 2014 under
the name RJF Labs, Inc. before changing its name to CLS Labs, Inc. on October
24, 2014. It was formed to commercialize a proprietary method of extracting
cannabinoids from cannabis plants and converting the resulting cannabinoid
extracts into concentrates such as oils, waxes, edibles and shatter. These
concentrates may be ingested in a number of ways, including through vaporization
via electronic cigarettes ("e-cigarettes"), and used for a variety of
pharmaceutical and other purposes. Testing in conjunction with two Colorado
growers of this extraction method and conversion process has revealed that it
produces a cleaner, higher quality product and a significantly higher yield than
the cannabinoid extraction processes currently existing in the marketplace.



On April 17, 2015, CLS Labs took its first step toward commercializing its
proprietary methods and processes by entering into the Colorado Arrangement
through its wholly owned subsidiary, CLS Labs Colorado, with certain Colorado
entities, including PRH. During 2017, we suspended our plans to proceed with the
Colorado Arrangement due to regulatory delays and have not yet determined if or
when we will pursue them again.



We have been issued a U.S. patent with respect to our proprietary method of
extracting cannabinoids from cannabis plants and converting the resulting
cannabinoid extracts into concentrates such as oils, waxes, edibles and shatter.
These concentrates may be ingested in a number of ways, including through
vaporization via electronic cigarettes, and used for a variety of pharmaceutical
and other purposes. Internal testing of this extraction method and conversion
process has revealed that it produces a cleaner, higher quality product and a
significantly higher yield than the cannabinoid extraction processes currently
existing in the marketplace. We have not yet commercialized our proprietary
process. We plan to generate revenues through licensing, fee-for-service and
joint venture arrangements related to our proprietary method of extracting
cannabinoids from cannabis plants and converting the resulting cannabinoid
extracts into saleable concentrates.



We intend to monetize our extraction and conversion method and generate revenues
through (i) the licensing of our patented proprietary methods and processes to
others, (ii) the processing of cannabis for others, and (iii) the purchase of
cannabis and the processing and sale of cannabis-related products. We plan to
accomplish this through the acquisition of companies, the creation of joint
ventures, through licensing agreements, and through fee-for-service arrangements
with growers and dispensaries of cannabis products. We believe that we can
establish a position as one of the premier cannabinoid extraction and processing
companies in the industry. Assuming we do so, we then intend to explore the
creation of our own brand of concentrates for consumer use, which we would sell
wholesale to cannabis dispensaries. We believe that we can create a "gold
standard" national brand by standardizing the testing, compliance and labeling
of our products in an industry currently comprised of small, local businesses
with erratic and unreliable product quality, testing practices and labeling. We
also plan to offer consulting services through Cannabis Life Sciences
Consulting, LLC, which will generate revenue by providing consulting services to
cannabis-related businesses, including growers, dispensaries and laboratories,
and driving business to our processing facilities. Finally, we intend to grow
through select acquisitions in secondary and tertiary markets, targeting newly
regulated states that we believe offer a competitive advantage. Our goal at this
time is to become a successful regional cannabis company.



                                       28

--------------------------------------------------------------------------------

Table of Contents




On December 4, 2017, we entered into the Acquisition Agreement with Alternative
Solutions to acquire the outstanding equity interests in the Oasis LLCs.
Pursuant to the Acquisition Agreement, as amended, we paid a non-refundable
deposit of $250,000 upon signing, which was followed by an additional payment of
$1,800,000 on February 5, 2018, for an initial 10% of Alternative Solutions and
each of the subsidiaries. At the closing of our purchase of the remaining 90% of
the ownership interests in Alternative Solutions and the Oasis LLCs, which
occurred on June 27, 2018, we paid the following consideration: $5,995,543 in
cash, a $4.0 million promissory note due in December 2019, and $6,000,000 in
shares of our common stock. The cash payment of $5,995,543 was less than the
$6,200,000 payment originally contemplated because we assumed an additional
$204,457 of liabilities. The Oasis Note, which was repaid in full in December
2019, was secured by all of the membership interests in Alternative Solutions
and the Oasis LLCs and by the assets of the Oasis LLCs. At that time, we applied
for regulatory approval to own an interest in the Oasis LLCs, which approval was
received on June 21, 2018. Just prior to closing, the parties agreed that we
would instead acquire all of the membership interests in Alternative Solutions,
the parent of the Oasis LLCs, from its members, and the membership interests in
the Oasis LLCs owned by members other than Alternative Solutions. We have
applied for regulatory approval to own our interest in the Oasis LLCs through
Alternative Solutions under the final structure of the transaction, which is
currently under review.



On October 31, 2018, the Company, CLS Massachusetts, Inc., a Massachusetts
corporation and a wholly-owned subsidiary of the Company ("CLS Massachusetts"),
and In Good Health, Inc., a Massachusetts corporation ("IGH"), entered into an
Option Agreement (the "IGH Option Agreement"). Under the terms of the IGH Option
Agreement, CLS Massachusetts had an exclusive option to acquire all of the
outstanding capital stock of IGH (the "IGH Option") during the period beginning
on the earlier of the date that is one year after the effective date of the
conversion and December 1, 2019 and ending on the date that was 60 days after
such date. If CLS Massachusetts exercised the IGH Option, the Company, a
wholly-owned subsidiary of the Company and IGH would enter into a merger
agreement (the form of which has been agreed to by the parties) (the "IGH Merger
Agreement"). At the effective time of the merger contemplated by the IGH Merger
Agreement, CLS Massachusetts would pay a purchase price of $47,500,000, subject
to reduction as provided in the IGH Merger Agreement, payable as follows: $35
million in cash, $7.5 million in the form of a five-year promissory note, and $5
million in the form of restricted common stock of the Company, plus $2.5 million
as consideration for a non-competition agreement with IGH's President, payable
in the form of a five-year promissory note. IGH and certain IGH stockholders
holding sufficient aggregate voting power to approve the transactions
contemplated by the IGH Merger Agreement had entered into agreements pursuant to
which such stockholders had, among other things, agreed to vote in favor of such
transactions. On October 31, 2018, as consideration for the IGH Option, we made
a loan to IGH, in the principal amount of $5,000,000, subject to the terms and
conditions set forth in that certain loan agreement, dated as of October 31,
2018 between IGH as the borrower and the Company as the lender. The loan was
evidenced by a secured promissory note of IGH, which bore interest at the rate
of 6% per annum and was to mature on October 31, 2021. To secure the obligations
of IGH to us under the loan agreement and the promissory note, the Company and
IGH entered into a security agreement dated as of October 31, 2018, pursuant to
which IGH granted to us a first priority lien on and security interest in all
personal property of IGH. If we did not exercise the Option on or prior to the
date that was 30 days following the end of the option period, the loan amount
was to be reduced to $2,500,000 as a break-up fee, subject to certain exceptions
set forth in the IGH Option Agreement. On August 26, 2019, the parties amended
the IGH Option Agreement to, among other things, delay the closing until January
2020. By letter agreement dated January 31, 2020, the parties extended the IGH
Option Agreement to February 4, 2020. On February 4, 2020, CLS Massachusetts
exercised the IGH Option.



By letter dated February 26, 2020, we informed IGH that as a result of its
breaches of the IGH Option, which remained uncured, an event of default had
occurred under the IGH Note. We further advised IGH that we were electing to
cause the IGH Note to bear interest at the default rate of 15% per annum
effective February 26, 2020 and to accelerate all amounts due under the IGH
Note. On March 3, 2020, we filed a claim for declaratory relief, among other
things, requesting the court declare that CLS Massachusetts had validly
exercised the IGH Option and instruct IGH to comply with its diligence requests
and ultimately execute a merger agreement with us. The dispute regarding whether
CLS Massachusetts properly exercised the IGH Option arose after CLS
Massachusetts delivered a notice of exercise to IGH and IGH subsequently
asserted that CLS Massachusetts' exercise was invalid. On February 27, 2021, IGH
notified us that it did not plan to make further payments under the IGH Note on
the theory that the Break-Up fee excused additional payments. We vehemently
disagreed with this assertion. During the twelve months ended May 31, 2021, we
impaired the remaining amounts due under the IGH Note in the amount of
$2,498,706, which includes $2,497,884 in principal and $822 in accrued interest.
As of August 31, 2021, the principal balance of the IGH Note was $0 and the
interest receivable was $0.



On June 14, 2021, the parties to the IGH lawsuit entered into a confidential
settlement agreement to resolve the action and a secured promissory note dated
and executed by IGH in favor of us and effective June 11, 2021 (the "IGH
Settlement Note"). Pursuant to the IGH Settlement Note, IGH shall pay us
$3,000,000, $1,000,000 of which was paid on or before July 12, 2021. The
remaining $2,000,000 and accrued interest is being paid in 12 equal monthly
installments, which began on August 12, 2021. During the three months ended
August 31, 2021, we received $1,174,082 under the IGH Settlement Note , which
includes $1,166,667 in principal and $7,415 in accrued interest.  As of August
31, 2021, $1,833,333 was due under the IGH Settlement Note. We record amounts
paid under the IGH Settlement Note as gains when payments are received.



                                       29

--------------------------------------------------------------------------------

Table of Contents




On January 4, 2018, former Attorney General Jeff Sessions rescinded the
memorandum issued by former Deputy Attorney General James Cole on August 29,
2013 (as amended on February 14, 2014, the "Cole Memo"), the Cole Banking
Memorandum, and all other related Obama-era DOJ cannabis enforcement
guidance. While the rescission did not change federal law, as the Cole Memo and
other DOJ guidance documents were not themselves laws, the rescission removed
the DOJ's formal policy that state-regulated cannabis businesses in compliance
with the Cole Memo guidelines should not be a prosecutorial priority. Notably,
former Attorney General Sessions' rescission of the Cole Memo has not affected
the status of the U.S. Department of the Treasury's Financial Crimes Enforcement
Network ("FinCEN") memorandum issued by the Department of Treasury, which
remains in effect. This memorandum outlines Bank Secrecy Act-compliant pathways
for financial institutions to service state-sanctioned cannabis businesses,
which echoed the enforcement priorities outlined in the Cole Memo. In addition
to his rescission of the Cole Memo, Attorney General Sessions issued a one-page
memorandum known as the "Sessions Memorandum". The Sessions Memorandum explains
the DOJ's rationale for rescinding all past DOJ cannabis enforcement guidance,
claiming that Obama-era enforcement policies are "unnecessary" due to existing
general enforcement guidance adopted in the 1980s, in chapter 9.27.230 of the
U.A. Attorneys' Manual ("USAM"). The USAM enforcement priorities, like those of
the Cole Memo, are based on the use of the federal government's limited
resources and include "law enforcement priorities set by the Attorney General,"
the "seriousness" of the alleged crimes, the "deterrent effect of criminal
prosecution," and "the cumulative impact of particular crimes on the community."
Although the Sessions Memorandum emphasizes that cannabis is a federally illegal
Schedule I controlled substance, it does not otherwise instruct U.S. Attorneys
to consider the prosecution of cannabis-related offenses a DOJ priority, and in
practice, most U.S. Attorneys have not changed their prosecutorial approach to
date. However, due to the lack of specific direction in the Sessions Memorandum
as to the priority federal prosecutors should ascribe to such cannabis
activities, there can be no assurance that the federal government will not seek
to prosecute cases involving cannabis businesses that are otherwise compliant
with state law.



William Barr served as United States Attorney General from February 14, 2019 to
December 23, 2020. The DOJ under Mr. Barr did not take a formal position on
federal enforcement of laws relating to cannabis. On March 11, 2021, United
States President Biden's nominee, Merrick Garland was sworn in as the U.S.
Attorney General. During his campaign, President Biden stated a policy goal to
decriminalize possession of cannabis at the federal level, but he has not
publicly supported the full legalization of cannabis. It is unclear what impact,
if any, the new administration will have on U.S. federal government enforcement
policy on cannabis. Nonetheless, there is no guarantee that the position of the
Department of Justice will not change.



We incurred a net loss of $15,890,514 for the year ended May 31, 2021, and net
income of $427,599 for the three months ended August 31, 2021, respectively,
resulting in an accumulated deficit of $92,736,638 as of May 31, 2021, which
deficit decreased to $92,309,039 as of August 31, 2021.  Although we achieved
net income during the first quarter of fiscal 2022, these conditions continue to
raise substantial doubt about our ability to continue as a going concern.



Recent Developments - COVID-19




On March 12, 2020, Governor Steven Sisolak declared a State of Emergency related
to the COVID-19 global pandemic. This State of Emergency was initiated due to
the multiple confirmed and presumptive cases of COVID-19 in the State of Nevada.
On March 17, 2020, pursuant to the Declaration of Emergency, Governor Sisolak
released the Nevada Health Response COVID-19 Risk Mitigation Initiative
("Initiative"). This Initiative provided guidance related to the March 12
Declaration of Emergency, requiring Nevadans to stay home and all nonessential
businesses to temporarily close to the public for thirty (30) days. In the
Initiative, it was declared that licensed cannabis stores and medical
dispensaries could remain open only if employees and consumers strictly adhered
to the social distancing protocols.



In light of the Initiative, Governor Sisolak issued Declaration of Emergency
Directive 003 on March 20, 2020 which mandated retail cannabis dispensaries to
operate as delivery only. On April 29, 2020, Governor Sisolak issued Declaration
of Emergency Directive 016 which amended the cannabis section of Directive 003
and permitted licensed cannabis dispensaries to engage in retail sales on a
curbside pickup or home delivery basis pursuant to guidance from the Cannabis
Compliance Board. Through Directive 016, licensed cannabis dispensaries were
able to begin curbside pickup on May 1, 2020 so long as the facility adhered to
protocols developed by the Cannabis Compliance Board ("CCB").



In accordance with Directive 016, the CCB released guidelines related to
curbside pickup requiring all facilities wishing to offer curbside pickup to
first submit and receive approval from the CCB. Serenity Wellness Center LLC
developed the required procedures and submitted and received State approval on
April 30, 2020 to conduct curbside pickup sales effective May 1, 2020. Further,
the City of Las Vegas required cannabis facilities to obtain a temporary 30-day
curbside pickup permit. Serenity Wellness Center LLC was issued its first
temporary curbside pickup permit from the City of Las Vegas on May 1, 2020.
Serenity Wellness Center LLC has subsequently received a temporary curbside
permit every thirty (30) days thereafter. Upon expiration every 30 days, the
City of Las Vegas reviews the licensee and determines if a new temporary permit
shall be issued.



                                       30

--------------------------------------------------------------------------------

Table of Contents




On May 7, 2020, Governor Sisolak issued Declaration of Emergency Directive 018.
Directive 018 worked to reopen the State of Nevada as a part of Phase One of the
Nevada United: Roadmap to Recovery Plan introduced by Governor Sisolak on April
30, 2020. Directive 018 provided that, in addition to curbside pickup or home
delivery, licensed cannabis dispensaries could engage in retail sales on an
in-store basis effective May 9, 2020, pursuant to guidance from the CCB. The CCB
required facilities wishing to engage in limited in-store retail sales to submit
Standard Operating Procedures and receive approval of the same. Serenity
Wellness Center LLC developed the required procedures and submitted and received
State approval on May 8, 2020 to conduct limited in-store retail sales effective
May 9, 2020. The City of Las Vegas did not require a separate permit for limited
in-store sales.



On July 31, 2020, Governor Sisolak issued Declaration of Emergency Directive 029
reaffirming The Nevada United: Roadmap to Recovery Plan. Directive 029 stated
that all directives promulgated pursuant to the March 12, 2020 Declaration of
Emergency or subsections thereof set to expire on July 31, 2020, would remain in
effect for the duration of the current state of emergency unless terminated
prior to that date by a subsequent directive or by operation of law associated
with lifting the Declaration of Emergency. Further, Directive 029, having become
effective at 11:59 PM on Friday, July 31, 2020 shall remain in effect until
terminated by a subsequent directive promulgated pursuant to the March 12, 2020
Declaration of Emergency, or dissolution or lifting of the Declaration of
Emergency itself, to facilitate the State's response to the COVID-19 pandemic.



The global pandemic of COVID-19 continues to evolve and the ways that our business may evolve to respond to the pandemic and the needs of our customers cannot be fully known.

Results of Operations for the Three Months Ended August 31, 2021 and 2020




The table below sets forth our expenses as a percentage of revenue for the
applicable periods:



                                                     Three Months Ended        Three Months Ended
                                                      August 31, 2021           August 31, 2020
Revenue                                                              100 %                     100 %
Cost of Goods Sold                                                    47 %                      47 %
Gross Margin                                                          53 %                      53 %
Selling, General, and Administrative Expenses                         53 %                      64 %
Interest expense, net                                                  8 %                      17 %
Gain on settlement of notes receivable                               (21 )%                      -




The table below sets forth certain statistical and financial highlights for the
applicable periods:



                                                     Three Months Ended       Three Months Ended
                                                      August 31, 2021          August 31, 2020
Number of Customers Served (Dispensary)                           65,092                   54,738
Revenue                                             $          5,500,710     $          3,780,869
Gross Profit                                        $          2,896,243     $          1,992,009
Gain on settlement of notes receivable              $         (1,174,082 )   $                  -
Net Income (Loss)                                   $            427,599     $         (1,145,036 )
EBITDA (1)                                          $          1,351,843     $           (241,674 )
Adjusted EBITDA (1)                                 $            194,475     $           (173,129 )




(1) EBITDA and Adjusted EBITDA are non-GAAP financial performance measures and
should not be considered as alternatives to net income(loss) or any other
measure derived in accordance with GAAP. These non-GAAP measures have
limitations as analytical tools and should not be considered in isolation or as
substitutes for analysis of our financial results as reported in accordance with
GAAP. Because not all companies use identical calculations, these presentations
may not be comparable to other similarly titled measures of other companies. As
required by the rules of the SEC, we provide below a reconciliation of the
non-GAAP financial measures contained herein to the most directly comparable
measure under GAAP. Management believes that EBITDA and Adjusted EBITDA provide
relevant and useful information, which is widely used by analysts, investors and
competitors in our industry as well as by our management. Adjusted EBITDA
excludes certain non-cash expenses not already excluded as part of EBITDA as
well as the impact of the significant litigation expenses, which were associated
with our action against IGH related to its breach of the IGH Option, and which
has been settled. By providing these non-GAAP profitability measures, management
intends to provide investors with a meaningful, consistent comparison of our
profitability measures for the periods presented.



                                       31

--------------------------------------------------------------------------------

Table of Contents

Reconciliation of net loss for the three months ended August 31, 2021 and 2020 to EBITDA and Adjusted EBITDA is in the table below:



                                                       Three Months Ended       Three Months Ended
                                                        August 31, 2021          August 31, 2020
Net Loss                                              $            427,599     $         (1,145,036 )
Add:
Interest expense, net                                 $            418,592     $            732,602
Provision for income taxes                            $            328,340     $                  -
Depreciation and amortization                         $            177,312     $            170,760
EBITDA                                                $          1,351,843     $           (241,674 )

Other adjustments:
Non-recurring cash payments for litigation            $             16,714     $             41,607
Non-recurring gain on settlement of note receivable   $         (1,174,082 )   $                  -
Non-cash compensation                                 $                  -     $             26,938
Adjusted EBITDA                                       $            194,475     $           (173,129 )




Revenues



We had revenue of $5,500,710 during the three months ended August 31, 2021, an
increase of $1,719,841, or 45%, compared to revenue of $3,780,869 during the
three months ended August 31, 2020. Our cannabis dispensary accounted for
$3,745,575, or 68%, of our revenue for the three months ended August 31, 2021,
an increase of $660,050, or 21%, compared to $3,085,525 during the three months
ended August 31, 2020. Dispensary revenue also increased during the first
quarter of fiscal year 2022 because our average sales per day increased from
$33,538 during the first quarter of fiscal 2021 to $40,713 during the first
quarter of fiscal 2022. Our cannabis production accounted for $1,755,135, or
32%, of our revenue for the three months ended August 31, 2021, an increase of
$1,059,791, or 152%, compared to $695,344 for the three months ended August 31,
2020.  The increase in production revenues for the first quarter of fiscal 2022
was primarily due to delays during the first quarter of fiscal 2021 in making
changes to our wholesale product mix dictated by market demand during
construction of our state-of-the-art manufacturing facility. Such changes have
now been implemented. The increase in wholesale revenue for the first quarter of
fiscal 2022 also was due to the impact of our improvements in purchasing and
timely delivery of products, increased toll processing customers, and
implementation of more effective systems and controls.



Cost of Goods Sold



Our cost of goods sold for the three months ended August 31, 2021 was
$2,604,467, an increase of $815,607, or 46%, compared to cost of goods sold of
$1,788,860 for the three months ended August 31, 2020. The increase in cost of
goods sold for the three months ended August 31, 2021 was due primarily to our
increase in sales during the quarter. Cost of goods sold was 47% of sales during
both the first quarter of fiscal 2022 and fiscal 2021 resulting in a 53% gross
margin for both years, which exceeds our target of 50%. Cost of goods sold
during the first quarter of fiscal 2022 primarily consisted of $2,276,088 of
product cost, $175,771 of state and local fees and taxes, and $128,544 of
supplies and materials.



Selling, General and Administrative Expenses




Selling, general and administrative expenses, or SG&A, increased by $491,351, or
approximately 20%, to $2,895,794 during the three months ended August 31, 2021,
compared to $2,404,443 for the three months ended August 31, 2020. The increase
in SG&A expenses for the three months ended August 31, 2021 was primarily due to
the use of a third-party marketing firm for campaigns to promote brand
awareness; payroll and related expenses due to an increase in commissions
related to increased sales and increased staffing needed to support this sales
growth; office and facilities costs incurred in connection with our expanded
manufacturing facility; and an increase in travel related expenses.



SG&A expense during the first quarter of fiscal 2022 was primarily attributable
to an aggregate of $2,359,196 in costs associated with operating the Oasis LLCs,
an increase of $559,758 compared to $1,799,438 during fiscal 2020. The major
components of the $522,799 increase in SG&A associated with the operation of the
Oasis LLCs during the three months ended August 31, 2021 compared to the three
months ended August 31, 2020 were as follows: sales, marketing, and advertising
costs of $446,666 compared to $132,033; lease, facilities and office costs of
$522,217 compared to $447,708; and payroll and related costs of $1,001,651
compared to $941,445. Payroll and marketing costs increased during the first
quarter of fiscal 2022 due to the growth in revenues of the Oasis LLCs during
the first quarter of fiscal 2022, our use of a third-party marketing firm for
campaigns to promote brand awareness,, and costs incurred in connection with our
response to COVID-19.  Lease, facilities, and office costs increased due to our
expanded production facility and due to costs incurred in connection with our
response to COVID-19.



                                       32

--------------------------------------------------------------------------------

Table of Contents




Finally, SG&A decreased by an aggregate of $68,406 during the first quarter of
fiscal 2022 as a result of a decrease in the expenses associated with the
ongoing implementation of other aspects of our business plan and our general
corporate overhead to an aggregate of $536,599, from $605,005 during the first
quarter of fiscal 2021. The major components of this decrease compared to the
first quarter of fiscal 2021 were as follows: non-cash compensation decreased by
$26,938; travel related expenses decreased by $25,362; and office and facilities
costs decreased by $15,352. These decreases were primarily due to not issuing
non-cash compensation to our officers or consultants during the first quarter of
fiscal 2022; a decline in travel due to the impact of COVID-19; and a decline in
spending on website design and development during the first quarter of fiscal
2022.


Gain on Settlement of Note Receivable




During the three months ended August 31, 2021, we recorded a gain on the
settlement of the IGH Note in the amount of $1,174,082; there was no comparable
transaction during the first quarter of the prior fiscal year. This gain on the
settlement arose after IGH notified us on February 27, 2021, that it did not
plan to make further payments in accordance with the terms of the IGH Note on
the theory that the Break-Up Fee excused such additional payments.  On June 14,
2021, the parties to the IGH lawsuit entered into a confidential settlement
agreement to resolve the action the IGH Settlement Note. Pursuant to the IGH
Settlement Note, IGH paid us $1,000,000 on or before June 21, 2021. The
remaining $2,000,000 and accrued interest is being paid in 12 equal monthly
installments, which commended on August 12, 2021.



Interest Expense, Net



Our interest expense, net of interest income, was $418,592 for the three months
ended August 31, 2021, a decrease of $314,010, or 43%, compared to $732,602 for
the three months ended August 31, 2020. The decrease in interest expense was
primarily due to the write-off of discounts on debentures in the amount $996,727
in connection with the amendment of U.S. Convertible Debentures 1, 2 and 4 and
the Canaccord Debentures during the fourth quarter of fiscal 2021. The decrease
in net interest expense for the first quarter of fiscal 2022 was partially
offset by a decrease in interest income during the first quarter of fiscal 2022
in the amount of $60,565, from $60,565 during the three months ended August 31,
2020 to $0 during the three months ended August 31, 2021.  This decrease
occurred due to the lower principal balance under the IGH Note.



Provision for Income Taxes



We recorded a provision for income taxes in the amount of $328,340 during the
three months ended August 31, 2021 compared to $0 during the three months ended
August 31, 2020. Although we have net operating losses that we believe are
available to us to offset this entire tax liability, which arises under Section
280E of the Code because we are a cannabis company, as a conservative measure,
we have accrued this liability.



Net Loss


Our net income for the three months ended August 31, 2021 was $427,599 compared to a net loss of $1,142,036 for the three months ended August 31, 2020, an improvement of $1,572,635, or 137%.

Liquidity and Capital Resources

The following table summarizes our total current assets, liabilities and working capital at August 31, 2021 and May 31, 2021:



                            August 31,        May 31,
                               2021             2021
Current Assets              $ 4,477,787     $  3,840,563

Current Liabilities $ 5,109,055 $ 4,984,485 Working Capital (Deficit) $ (631,268 ) $ (1,143,922 )





At August 31, 2021, we had a working capital deficit of $631,268, a decrease of
$512,654 from the working capital deficit of $1,143,922 we had at May 31, 2021.
Our working capital at August 31, 2021, includes $1,961,091 of cash. Our working
capital was increased primarily due to an increase in our inventory of $454,468,
and an increase in cash and cash equivalents of $295,828, which was partially
offset by a $328,340 liability for income taxes, which taxes are imposed because
we are a cannabis company.  We believe we have net operating losses sufficient
to offset this income tax liability in full.



Our working capital needs will likely continue to increase, and if we require
additional funds to meet them, we will seek additional debt or equity financing.
Until the first quarter of fiscal 2022, we operated at a loss. Over the next
twelve months we will likely require additional capital to pursue the
implementation of our business plan, including the development of other revenue
sources, such as possible acquisitions and joint venture.



                                       33

--------------------------------------------------------------------------------

Table of Contents




During the next twelve months we do not have any capital projects planned. We
may pursue additional acquisitions and joint ventures in the next twelve months
but we have not entered into any definitive agreements with respect to either
additional acquisitions or joint ventures or the capital necessary to finance
them. If we do pursue any acquisitions or joint ventures, we would likely fund
them with the proceeds of future equity sales, warrant exercise proceeds, loans
or seller financings. We have not pursued the availability of any such sources
at present.



Although our revenues are expected to grow as we expand our operations, we only
achieved net income for the first time this quarter. Although we believe we have
funds sufficient to sustain our operations at their current level, if we require
additional cash, we expect to obtain the necessary funds as described above;
however, our prospects must be considered in light of the risks, expenses and
difficulties frequently encountered by companies in their early stage of
operations. To address these risks, we must, among other things, seek growth
opportunities through additional debt and/or equity investments and acquisitions
in our industry, successfully execute our business strategy, including our
planned expansion and acquisitions, and successfully navigate the COVID-19
business environment in which we currently operate as well as any changes that
may arise in the cannabis regulatory environment. We cannot assure that we will
be successful in addressing such risks, and the failure to do so could have a
material adverse effect on our business prospects, financial condition and
results of operations.



Cash flows used in operating activities were $785,275 during the three months
ended August 31, 2021, an increase of $81,730, or approximately 12%, compared to
$703,545 during the three months ended August 31, 2020.  In deriving cash flows
used in operating activities from the net income (loss) for the first quarters
of fiscal 2022 and fiscal 2021, there were net amounts of $198,609 and $567,018,
respectively, of non-cash items that were added back to the net income (loss)
for each such quarter.  For the first quarter of fiscal 2022, the most
significant item added back to net income was $1,174,082 related to the gain on
settlement of the IGH Note ; there was no comparable charge during the first
quarter of fiscal 2021.  We also recorded the following significant items in the
first quarter of fiscal 2022: $21,297 of amortization of debt discounts during
the first quarter of fiscal 2022 compared to $395,070 during the first quarter
of fiscal 2021; and $177,312 of depreciation and amortization during the first
quarter of fiscal 2022 compared to $170,760 during the first quarter of fiscal
2021.



Finally, our cash used in operating activities was affected by changes in the
components of working capital. The amounts of the components of working capital
fluctuate for a variety of reasons, including management's expectation of
required inventory levels; the amount of accrued interest, both receivable and
payable; the amount of prepaid expenses; the amount of accrued compensation and
other accrued liabilities; our accounts payable and accounts receivable
balances; and the capitalization of right of use assets and liabilities
associated with operating leases. The overall net change in the components of
working capital resulted in a decrease in cash from operating activities in the
amount of $237,401 during the three months ended August 31, 2021, compared to a
decrease in cash from operating activities of $131,519 during the first fiscal
quarter of fiscal 2021.  The more significant changes for the three months ended
August 31, 2021 were as follows: inventory increased by $454,468, compared to an
increase of $142,802 during the first quarter of the prior fiscal year because
of our improvements in purchasing and timely delivery of products, increased
toll processing customers, and implementation of more effective systems and
controls; accounts payable and accrued expenses decreased by $229,793 compared
to an increase of $237,820 during the first quarter of the prior fiscal year due
to increased payment of trade payables and an increase in city and state sales
and excise taxes due; accounts receivable decreased by $160,306 compared to an
increase of $307,087 during the first quarter of the prior fiscal year due to an
increase in collection of receivables; and accrued interest decreased by $3,747
compared to an increase of $258,114 during the first quarter of the prior fiscal
year due to the lower principal balance of our convertible debentures as a
result of conversions during the first quarter of fiscal 2022.



Cash flows provided by investing activities were $1,081,103 for the three months
ended August 31, 2021, an increase of $416,024, or 63%, compared to cash flow
provided by investing activities of $665,079 during the three months ended
August 31, 2020.  During the three months ended August 31, 2021 and 2020, we
received principal payments on the IGH Note in the amounts of $1,174,082, and
$750,000, respectively.



                                       34

--------------------------------------------------------------------------------

  Table of Contents



Third Party Debt


The table below summarizes the status of our third party debt and reflects whether such debt remains outstanding, has been repaid, or has been converted into or exchanged for our common stock:



Name of            Original        Outstanding
Note           Principal Amount    or Repaid     Payment Details

Oasis Note    $        4,000,000   Repaid        Repaid

                                                 Due October 26-31,
                                                 2021. Amount due
                                                 includes
2018 U.S.                                        capitalized
Convertible                                      interest of
Debentures    $          365,991   Outstanding   $40,991.

                                                 Due October 22-25,
Amended and                                      2022. Amount due
Restated                                         includes
2018 U.S.                                        capitalized
Convertible                                      interest of
Debentures    $        6,229,672   Outstanding   $697,672.

                                                 Due December 2022.
                                                 Amount includes
                                                 capitalized
                                                 interest of
                                                 $1,514,006 less
                                                 conversion of
2018                                             principal in the
Convertible                                      amount of
Debentures    $       13,219,150   Outstanding   $306,856.




Oasis Note



On June 27, 2018, we closed on the purchase of the remaining 90% of the
membership interests of Alternative Solutions and the Oasis LLCs.  The closing
occurred pursuant to the Acquisition Agreement dated December 4, 2017, as
amended.  On such date, we made the payments to indirectly acquire the remaining
90% of the Oasis LLCs, which were equal to cash in the amount of $5,995,543, a
$4.0 million promissory note due in December 2019 (the "Oasis Note"), and
22,058,823 shares of our common stock. The cash payment of $5,995,543 was less
than the $6,200,000 payment originally contemplated because we assumed an
additional $204,457 in liabilities. The Oasis Note bears interest at the rate of
6% per annum.  The principal amount of the Oasis Note was reduced in August
2019, in accordance with the terms of the Acquisition Agreement, as a result of
the settlement of the dispute between the former owners of Alternative Solutions
and 4Front Advisors, a consultant to Alternative Solutions.   The terms of the
settlement with 4Front Advisors are confidential.  The Oasis Note is secured by
all of the membership interests in Alternative Solutions and the Oasis LLCs and
by the assets of the Oasis LLCs.  On December 31, 2019, we repaid the remaining
amount of the note, which comprised $1,363,925 of principal and $370,370 of
interest.



2018 U.S. Convertible Debenture Offering




Between October 22, 2018 and November 2, 2018, we entered into six subscription
agreements, pursuant to which we agreed to sell, $5,857,000 in original
principal amount of convertible debentures in minimum denominations of $1,000
each for an aggregate purchase price of $5,857,000.



Under the original terms, the debentures bear interest, payable quarterly, at a
rate of 8% per annum, with capitalization of accrued interest on a quarterly
basis for the first 18 months, by increasing the then-outstanding principal
amount of the debentures. The debentures originally matured on a date that was
three years following their issuance. The debentures were convertible into units
at a conversion price of $0.80 per unit. Each unit consists of (i) one share of
our common stock, par value $0.001 and (ii) one-half of one warrant, with each
warrant exercisable for three years to purchase a share of common stock at an
initial price of $1.10. The warrants also provided that we could force their
exercise at any time after the bid price of our common stock exceeds $2.20 for a
period of 20 consecutive business days. The debentures include a provision for
the capitalization of accrued interest on a quarterly basis for the first 18
months. After capitalizing accrued interest in the aggregate amount of $738,663,
the aggregate principal amount of the debentures increased to $6,595,663.



The debentures have other features, such as mandatory conversion in the event
our common stock trades at a particular price over a specified period of time
and required redemption in the event of a "Change in Control" of the Company.
The debentures are unsecured obligations of the Company and rank pari passu in
right of payment of principal and interest with all other unsecured obligations
of the Company. The warrants have anti-dilution provisions that provide for an
adjustment to the exercise price in the event of a future sale of our common
stock at a lower price, subject to certain exceptions as set forth in the
warrant.



                                       35

--------------------------------------------------------------------------------

Table of Contents




On July 26, 2019, we entered into amendments to the debentures with four of the
purchasers, pursuant to which we agreed to reduce the conversion price of the
original debentures if, in general, we issue or sell common stock, or warrants
or options exercisable for common stock, or any other securities convertible
into common stock, in a capital raising transaction, at a consideration per
share, or exercise or conversion price per share, as applicable, less than the
conversion price of the original debentures in effect immediately prior to such
issuance. In such case, the conversion price of the original debentures will be
reduced to such issuance price. The amendments also provided that, if a dilutive
issuance occurs, the warrant to be issued upon conversion will be exercisable at
a price equal to 137.5% of the Adjusted Conversion Price at the time of
conversion of the debenture. If a dilutive issuance occurs, the form of warrant
attached to the subscription agreement would be amended to change the Initial
Exercise Price, as defined therein, to be the Revised Warrant Exercise Price.



The Debenture Amendment (as hereafter defined) was a dilutive issuance. As a
result, the conversion price of the convertible debentures was automatically
reduced from $0.80 per unit to $0.30 per unit and the form of warrant attached
to the subscription agreement will be amended to reduce the exercise price from
$1.10 per share of common stock to 137.5% of the debenture conversion price
(presently $0.4125 per share of common stock).



On April 15, 2021 and April 19, 2021, we amended the three of the purchasers'
debentures and subscription agreements in order to (i) reduce the conversion
price of the debentures from $0.80 per unit to $0.30 per unit, and (ii) extend
the maturity date of the debentures by one year to four (4) years from the
execution date of the debentures. The subscription agreements, as amended, also
provide that we will file a registration statement to register for resale all of
the shares of common stock issuable to these three purchasers upon conversion of
the debentures and the exercise of the warrants issuable upon conversion of such
debentures. Each warrant issuable pursuant to the debentures is exercisable for
one share of common stock at a price equal to 137.5% of the conversion price
(presently $0.4125 per share) for a period of three-years from the earlier of
the date of issuance of the warrant or the effectiveness of a registration
statement registering the warrant shares.



2018 Convertible Debenture Offering




On December 12, 2018, we entered into an agency agreement with two Canadian
agents regarding a private offering of up to $40 million of convertible
debentures of the Company at an issue price of $1,000 per debenture (the
"Canaccord Debentures"). The agents sold the convertible debentures on a
commercially reasonable efforts private placement basis. Each debenture was
convertible into units of the Company at the option of the holder at a
conversion price of $0.80 per unit at any time prior to the close of business on
the last business day immediately preceding the maturity date of the debentures,
being the date that is three (3) years from the closing date of the offering
(the "2018 Convertible Debenture Offering"). Each unit will be comprised of one
share of common stock and a warrant to purchase one-half of a share of common
stock. Each warrant was initially exercisable for one share of common stock at a
price of $1.10 per warrant for a period of 36 months from the closing date.



We closed the 2018 Convertible Debenture Offering on December 12, 2018, issuing
$12,012,000 million in 8% senior unsecured convertible debentures at the initial
closing. At the closing, we paid the agents: (A)(i) a cash fee of $354,000 for
advisory services provided to us in connection with the offering; (ii) a cash
commission of $720,720, equivalent to 6.0% of the aggregate gross proceeds
received at the closing of the offering; (B)(i) an aggregate of 184,375 units
for advisory services; and (ii) a corporate finance fee equal to 375,375 units,
which is the number of units equal to 2.5% of the aggregate gross proceeds
received at the closing of the offering divided by the conversion price; and
(C)(i) an aggregate of 442,500 advisory warrants; and (ii) 900,900 broker
warrants, which was equal to 6.0% of the gross proceeds received at the closing
of the offering divided by the conversion price. During the year ended May 31,
2020, principal in the amount of $25,856 was converted into 32,319 shares of
common stock. The debentures include a provision for the capitalization of
accrued interest on a quarterly basis for the first 18 months. Accrued interest
in the amount of $1,514,006 was capitalized, and the principal amount of the
debentures is $13,500,150.



The debentures are unsecured obligations of the Company, rank pari passu in
right of payment of principal and interest and were issued pursuant to the terms
of a debenture indenture, dated December 12, 2018, between the Company and
Odyssey Trust Company as the debenture trustee. The debentures bear interest at
a rate of 8% per annum from the closing date, payable on the last business day
of each calendar quarter.



Beginning on the date that is four (4) months plus one (1) day following the
closing date, we could force the conversion of all of the principal amount of
the then outstanding debentures at the conversion price on not less than 30
days' notice should the daily volume weighted average trading price, or VWAP, of
our common stock be greater than $1.20 per share for the preceding 10
consecutive trading days.



Upon a change of control of the Company, holders of the debentures have the
right to require us to repurchase their debentures at a price equal to 105% of
the principal amount of the debentures then outstanding plus accrued and unpaid
interest thereon. The debentures also contain standard anti-dilution provisions.



                                       36

--------------------------------------------------------------------------------

Table of Contents




On March 31, 2021, the holders of the Canaccord Debentures approved the
amendment of the indenture related to the Canaccord Debentures (the "Debenture
Amendment") to: (i) extend the maturity date of the Canaccord Debentures from
December 12, 2021 to December 12, 2022; (ii) reduce the conversion price from
$0.80 per unit (as such term is defined in the indenture) to $0.30 per unit;
(iii) reduce the mandatory conversion VWAP threshold from $1.20 to $0.60 per
share; and (iv) amend the definitions of "Warrant" and "Warrant Indenture" (as
such terms are defined in the indenture), to reduce the exercise price of each
warrant to $0.40 per share of our common stock. Simultaneously, we amended the
warrant indenture to make conforming amendments and extend the expiration date
of the warrants to March 31, 2024.



If, at the time of exercise of any warrant in accordance with the warrant
indenture, there is no effective registration statement under the Securities Act
covering the resale by the holder of a portion of the shares of common stock to
be issued upon exercise of the warrant, or the prospectus contained therein is
not available for the resale of the shares of common stock by the holder under
the Securities Act by reason of a blackout or suspension of use thereof, then
the warrants may be exercised, in part for that portion of the shares of common
stock not registered for resale by the holder under an effective registration
statement or in whole in the case of the prospectus not being available for the
resale of such shares of common stock, at such time by means of a "cashless
exercise" in which the holder shall be entitled to receive a number of shares of
common stock equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where: A = the last volume weighted average price, or VWAP, for the trading day
immediately preceding the time of delivery of the exercise form giving rise to
the applicable "cashless exercise"; B = the exercise price of the warrant; and X
= the number of shares of common stock that would be issuable upon exercise of
the warrant in accordance with the terms of such warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.



Pursuant to the agency agreement, we granted the agents an option to increase
the offering by an additional $6 million in principal amount of debentures,
which option was not exercised by the agents prior to the closing date of the
offering.



Pursuant to the agency agreement and the subscription agreements signed by
investors in the offering, we granted certain registration rights to the holders
of the debentures pursuant to which we agreed to prepare and file a registration
statement with the SEC to register the resale by the original purchasers of the
debentures of the shares of common stock issuable upon conversion of the
debentures or exercise of the warrants.



Sales of Equity


The Canaccord Special Warrant Offering




On June 20, 2018, we executed an agency agreement with Canaccord Genuity Corp.
and closed on a private offering of our Special Warrants for aggregate gross
proceeds of CD$13,037,859 (USD$9,785,978). In connection therewith, we also
entered into a Special Warrant Indenture and a Warrant Indenture with Odyssey
Trust Company, as special warrant agent and warrant agent.



Pursuant to the offering, we issued 28,973,014 special warrants at a price of
CD$0.45 (USD$0.34) per Special Warrant. Each Special Warrant was automatically
exercised, for no additional consideration, into Units on November 30, 2018.



Each Unit consisted of one Unit Share and one Warrant to purchase one share of
common stock. Each Warrant was to be exercisable at a price of CD$0.65 for three
years after our common stock was listed on a recognized Canadian stock exchange,
subject to adjustment in certain events. Because we did not receive a receipt
from the applicable Canadian securities authorities for the qualifying
prospectus by August 20, 2018, each Special Warrant entitled the holder to
receive 1.1 Units (instead of one (1) Unit); provided, however, that any
fractional entitlement to penalty units was rounded down to the nearest whole
penalty unit.



In connection with the Special Warrant Offering, we paid a cash commission and
other fees equal to CD$1,413,267 (USD$1,060,773), a corporate finance fee equal
to 1,448,651 Special Warrants with a fair value of USD$1,413,300, and 2,317,842
Broker Warrants. Each Broker Warrant entitles the holder thereof to acquire one
unit at a price of CD$0.45 per unit for a period of 36 months from the date that
our common stock is listed on a recognized Canadian stock exchange, subject to
adjustment in certain events. Our common stock commenced trading on the Canadian
Stock Exchange on January 7, 2019. During the year ended May 31, 2020, we also
issued investors 3,042,167 Special Warrants with a fair value of $7,142,550 as a
penalty for failure to timely effect a Canadian prospectus with regard to the
securities underlying the Special Warrants.



                                       37

--------------------------------------------------------------------------------

  Table of Contents



The Navy Capital Investors



Effective July 31, 2018, we entered into a subscription agreement with Navy
Capital Green International, Ltd., a British Virgin Islands limited company
("Navy Capital"), pursuant to which we agreed to sell to Navy Capital, for a
purchase price of $3,000,000, 7,500,000 units ($0.40 per unit), representing (i)
7,500,000 shares of our common stock, and (ii) three-year warrants to purchase
an aggregate of 7,500,000 shares of our common stock (the "Navy Warrant Shares")
at an exercise price of $0.60 per share of common stock (the "Navy Capital
Offering"). We valued the warrants using the Black-Scholes valuation model, and
allocated gross proceeds in the amount of $1,913,992 to the common stock and
$1,086,008 to the warrants. The closing occurred on August 6, 2018. In the
subscription agreement, we also agreed to file, on or before November 1, 2018, a
registration statement with the SEC registering the shares of common stock and
Navy Warrant Shares issued to Navy Capital. If we failed to file the
registration statement on or before that date, we were required to issue to Navy
Capital an additional number of units equal to ten percent (10%) of the units
originally subscribed for by Navy Capital (which would include additional
warrants at the original exercise price). On August 29, 2019, we filed a
registration statement with the SEC which included the shares of common stock
and Navy Warrant Shares issued to Navy Capital. The warrant is exercisable from
time to time, in whole or in part for three years. The warrant has anti-dilution
provisions that provide for an adjustment to the exercise price in the event of
a future issuance or sale of common stock at a lower price, subject to certain
exceptions as set forth in the warrant. As a result of the Debenture Amendment,
conversion of the debentures issued in the 2018 Convertible Debenture Offering
will trigger this provision and reduce the exercise price of the warrants. The
warrant also provides that it is callable at any time after the bid price of our
common stock exceeds 120% of the exercise price of the warrant for a period of
20 consecutive business days. This warrant expired on July 31, 2021.



Between August 8, 2018 and August 10, 2018, we entered into five subscription
agreements, pursuant to which we sold, for an aggregate purchase price of
$2,750,000, 6,875,000 units ($0.40 per unit), representing (i) 6,875,000 shares
of our common stock, and (ii) three-year warrants to purchase an aggregate of
6,875,000 shares of our common stock at an exercise price of $0.60 per share of
common stock. We valued the warrants using the Black-Scholes valuation model,
and allocated gross proceeds in the amount of $1,670,650 to the common stock and
$1,079,350 to the warrants. These warrants expired on August 7, 2021. The
balance of the terms set forth in the subscription agreements are the same as
the terms in the Navy Capital subscription agreement summarized above.



Oasis Cannabis Transaction



On December 4, 2017, we entered into the Acquisition Agreement, with Alternative
Solutions for us to acquire all of the outstanding equity interests in
Alternative Solutions and the Oasis LLCs. Pursuant to the Acquisition Agreement,
we paid a non-refundable deposit of $250,000 upon signing, which was followed by
an additional payment of $1,800,000 approximately 45 days thereafter and were to
receive, upon receipt of applicable regulatory approvals, an initial 10% of each
of the Oasis LLCs. Regulatory approvals were received and the 10% membership
interests were transferred to us.



On June 27, 2018, we closed on the purchase of the remaining 90% of the
membership interests in Alternative Solutions and the Oasis LLCs from the owners
thereof (excluding Alternative Solutions). The closing consideration was as
follows: $5,995,543 in cash, a $4.0 million promissory note due in December
2019, known as the Oasis Note, and $6,000,000 in shares of our common stock. The
cash payment of $5,995,543 was less than the $6,200,000 payment originally
contemplated because the Company assumed an additional $204,457 of liabilities.



The number of shares to be issued was computed as follows: $6,000,000 divided by
the lower of $1.00 or the conversion price to receive one share of our common
stock in our first equity offering of a certain minimum size that commenced in
2018, multiplied by 80%. This price was determined to be $0.272 per share. The
Oasis Note was secured by a first priority security interest over our membership
interests in Alternative Solutions and the Oasis LLCs, and by the assets of each
of the Oasis LLCs and Alternative Solutions. We also delivered a confession of
judgment to a representative of the former owners of Alternative Solutions and
the Oasis LLCs (other than Alternative Solutions) that would generally become
effective upon an event of default under the Oasis Note or failure to pay
certain other amounts when due.  We repaid the Oasis Note in full in December
2019.



At the time of closing of the Acquisition Agreement, Alternative Solutions owed
certain amounts to a consultant known as 4Front Advisors, which amount was in
dispute. In August 2019, we made a payment to this company to settle this
dispute and the Oasis Note was reduced accordingly.



                                       38

--------------------------------------------------------------------------------

Table of Contents




The former owners of Alternative Solutions and the Oasis LLCs (other than
Alternative Solutions) became entitled to a $1,000,000 payment from us because
the Oasis LLC maintained an average revenue of $20,000 per day during the 2019
calendar year. We made a payment in the amount of $850,000 to the sellers on May
27, 2020. We deposited the balance due to sellers of $150,000 with an escrow
agent to hold pending the outcome of a tax audit. During the year ended May 31,
2020, the State of Nevada notified the Oasis LLCs that it would be conducting a
tax audit for periods both before and after the closing of the sale to CLS. The
Oasis LLCs have not yet received the demand from the State of Nevada with the
precise amount due and the amount escrowed is our best estimate of the
pre-closing tax liability If the ultimate tax liability is less than $150,000,
the balance of the escrowed amount will be paid to sellers. As of May 31, 2020,
the $150,000 remains a liability on the Company's balance sheet and $150,000 is
recorded in an escrow account in the asset section of the Company's balance
sheet.



We received final regulatory approval to own the membership interests in the
Oasis LLCs on December 12, 2018. We have applied for regulatory approval to own
our interest in the Oasis LLCs through Alternative Solutions, which is currently
under review.



Consulting Agreements



We periodically use the services of outside investor relations consultants.
During the year ended May 31, 2016, pursuant to a consulting agreement, we
agreed to issue 10,000 shares of common stock per month, valued at $11,600 per
month, to a consultant in exchange for investor relations consulting services.
The consulting agreement was terminated during the first month of its term. The
parties are in discussions regarding whether any shares of our common stock have
been earned and it is uncertain whether any shares will be issued. As of May 31,
2021, we included 20,000 shares of common stock, valued at $23,200 in stock
payable on the accompanying balance sheets. The shares were valued based on the
closing market price on the grant date.



On December 29, 2015, pursuant to a consulting agreement, we agreed to issue
25,000 shares of common stock per month, valued at $21,250, to a consultant in
exchange for investor relations consulting services. The consulting agreement
was terminated during the first month of its term. The parties are in
discussions regarding whether any shares of our common stock have been earned
and it is uncertain whether any shares will be issued. As of May 31, 2021, we
had 50,000 shares of common stock, valued at $42,500 included in stock payable
on the accompanying balance sheet. The shares were valued based on the closing
market price on the grant date.



On August 16, 2019, we amended a consulting agreement whereby we agreed to issue
up to 200,000 shares of common stock plus pay certain amounts in exchange for
the consultant's development for us of a corporate finance and investor
relations campaign, which services will be provided over a six month period.  We
issued 100,000 shares of common stock to this consultant in full satisfaction of
this agreement before this agreement was terminated.



Going Concern



Our financial statements were prepared using accounting principles generally
accepted in the United States of America applicable to a going concern, which
contemplate the realization of assets and liquidation of liabilities in the
normal course of business. We have incurred continuous losses from operations
since inception, and have an accumulated deficit of $92,309,039 as of August 31,
2021, compared to $92,736,638, as of May 31, 2021. We had a working capital
deficit of $631,268 as of August 31, 2021, compared to a working capital deficit
of $1,143,922 at May 31, 2021. The report of our independent auditors for the
year ended May 31, 2021 contained a going concern qualification. Our ability to
continue as a going concern must be considered in light of the problems,
expenses, and complications frequently encountered by early stage companies.



Our ability to continue as a going concern is dependent on our ability to
generate sufficient cash from operations to meet our cash needs, to borrow
capital and to sell equity to support our plans to acquire operating businesses,
open processing facilities and finance ongoing operations There can be no
assurance that we will be successful in our efforts to raise additional debt or
equity capital and/or that cash generated by our future operations will be
adequate to meet our needs. These factors, among others, indicate that we may be
unable to continue as a going concern for a reasonable period of time.



Off-Balance Sheet Arrangements




We do not have any off-balance sheet arrangements that have, or are reasonably
likely to have, a current or future effect on our financial condition, changes
in financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that are material to investors.



                                       39

--------------------------------------------------------------------------------

  Table of Contents



Critical Accounting Estimates



Management uses various estimates and assumptions in preparing our financial
statements in accordance with generally accepted accounting principles. These
estimates and assumptions affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. Accounting estimates that are the most important to the
presentation of our results of operations and financial condition, and which
require the greatest use of judgment by management, are designated as our
critical accounting estimates. We have the following critical accounting
estimates:



? Estimates and
  assumptions
  regarding the
  deductibility of
  expenses for
  purposes of Section
  280E of the
  Internal Revenue
  Code: Management
  evaluates the
  expenses of its
  manufacturing and
  retail operations
  and makes certain
  judgments regarding
  the deductibility
  of various expenses
  under Section 280E
  of the Internal
  Revenue Code based
  on its
  interpretation of
  this regulation and
  its subjective
  assumptions about
  the categorization
  of these expenses.




? Estimates and
  assumptions used in
  the valuation of
  derivative
  liabilities:
  Management utilizes
  a lattice model to
  estimate the fair
  value of derivative
  liabilities. The
  model includes
  subjective
  assumptions that
  can materially
  affect the fair
  value estimates.




? Estimates and
  assumptions used in
  the valuation of
  intangible assets.
  In order to value
  our intangible
  assets, management
  prepares multi-year
  projections of
  revenue, costs of
  goods sold, gross
  margin, operating
  expenses, taxes and
  after tax margins
  relating to the
  operations
  associated with the
  intangible assets
  being valued. These
  projections are
  based on the
  estimates of
  management at the
  time they are
  prepared and
  include subjective
  assumptions
  regarding industry
  growth and other
  matters.



Recently Issued Accounting Standards




Accounting standards promulgated by the Financial Accounting Standards Board
(the "FASB") are subject to change. Changes in such standards may have an impact
on our future financial statements. The following are a summary of recent
accounting developments.



In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for
Goodwill Impairment, which simplifies the subsequent measurement of goodwill by
eliminating Step 2 from the goodwill impairment test. In computing the implied
fair value of goodwill under Step 2, current U.S. GAAP requires the performance
of procedures to determine the fair value at the impairment testing date of
assets and liabilities (including unrecognized assets and liabilities) following
the procedure that would be required in determining the fair value of assets
acquired and liabilities assumed in a business combination. Instead, the
amendments under this ASU require the goodwill impairment test to be performed
by comparing the fair value of a reporting unit with its carrying amount. An
impairment charge should be recognized for the amount by which the carrying
amount exceeds the reporting unit's fair value; however, the loss recognized
should not exceed the total amount of goodwill allocated to that reporting unit.
The ASU became effective for us on January 1, 2020. The amendments in this ASU
were applied on a prospective basis. During the year ended May 31, 2020, the
Company recorded an impairment of goodwill in the amount of $25,185,003 pursuant
to ASU No. 2017-04.



In May 2017, the FASB issued ASU No. 2017-09, Stock Compensation - Scope of
Modification Accounting, which provides guidance on which changes to the terms
or conditions of a share-based payment award require an entity to apply
modification accounting. The ASU requires that an entity account for the effects
of a modification unless the fair value (or calculated value or intrinsic value,
if used), vesting conditions and classification (as equity or liability) of the
modified award are all the same as for the original award immediately before the
modification. The ASU became effective for us on January 1, 2018, and is applied
to an award modified on or after the adoption date. Adoption of ASU 2017-09 did
not have a material effect on the Company's financial statements.



In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260),
Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging
(Topic 815). The amendments in Part I of this update change the classification
analysis of certain equity-linked financial instruments (or embedded features)
with down round features. When determining whether certain financial instruments
should be classified as liabilities or equity instruments, a down round feature
no longer precludes equity classification when assessing whether the instrument
is indexed to an entity's own stock. The amendments also clarify existing
disclosure requirements for equity-classified instruments. As a result, a
freestanding equity-linked financial instrument (or embedded conversion option)
no longer would be accounted for as a derivative liability at fair value as a
result of the existence of a down round feature. For freestanding equity
classified financial instruments, the amendments require entities that present
earnings per share (EPS) in accordance with Topic 260 to recognize the effect of
the down round feature when it is triggered. That effect is treated as a
dividend and as a reduction of income available to common shareholders in basic
EPS. Convertible instruments with embedded conversion options that have down
round features are now subject to the specialized guidance for contingent
beneficial conversion features (in Subtopic 470-20, Debt-Debt with Conversion
and Other Options), including related EPS guidance (in Topic 260). The
amendments in Part II of this update recharacterize the indefinite deferral of
certain provisions of Topic 480 that now are presented as pending content in the
Codification, to a scope exception.



                                       40

--------------------------------------------------------------------------------

Table of Contents




These amendments do not have an accounting effect. For public business entities,
the amendments in Part I of this update are effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2018.
Early adoption is permitted for all entities, including adoption in an interim
period. If an entity early adopts the amendments in an interim period, any
adjustments should be reflected as of the beginning of the fiscal year that
includes that interim period.



Effective June 1, 2018, we adopted Accounting Standards Codification ("ASC") 606
- Revenue from Contracts with Customers. Under ASC 606, we recognize revenue
from the commercial sales of products and licensing agreements by applying the
following steps: (1) identify the contract with a customer; (2) identify the
performance obligations in the contract; (3) determine the transaction price;
(4) allocate the transaction price to each performance obligation in the
contract; and (5) recognize revenue when each performance obligation is
satisfied. For the comparative periods, revenue has not been adjusted and
continues to be reported under ASC 605 - Revenue Recognition. Under ASC 605,
revenue is recognized when the following criteria are met: (1) persuasive
evidence of an arrangement exists; (2) the performance of service has been
rendered to a customer or delivery has occurred; (3) the amount of fee to be
paid by a customer is fixed and determinable; and (4) the collectability of the
fee is reasonably assured. There was no impact on our financial statements as a
result of adopting ASC 606.



On June 1, 2018, we adopted ASU 2017-11 and accordingly reclassified the fair
value of the reset provisions embedded in convertible notes payable and certain
warrants with embedded anti-dilutive provisions from liability to equity in the
aggregate amount of $1,265,751.



There are various other updates recently issued, most of which represented
technical corrections to the accounting literature or application to specific
industries and are not expected to a have a material impact on our consolidated
financial position, results of operations or cash flows.

© Edgar Online, source Glimpses

All news about CLS HOLDINGS USA, INC.
01/14OUTPERFORMING THE MARKET : CLS Holdings USA, Inc. Reports Its Second Quarter Results with ..
AQ
01/12CLS HOLDINGS USA, INC. Management's Discussion and Analysis of Financial Condition and..
AQ
01/12CLS Holdings USA, Inc. Reports Earnings Results for the Second Quarter and Six Months E..
CI
2021CLS Holdings USA, Inc. announced a financing transaction
CI
2021CLS Holdings USA, Inc. Announces November Results With Record Breaking Gross Profit Mar..
AQ
2021CLS Holdings USA, Inc. Announces New Brand Manager, Dani Baranowski, for The Company's ..
AQ
2021CLS HOLDINGS USA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021CLS HOLDINGS USA, INC. : Entry into a Material Definitive Agreement, Financial Statements ..
AQ
2021A POSITIVE OUTLOOK : CLS Holdings USA, Inc. Reports Its First Ever Profitable Quarter with..
PU
2021CLS USA : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
More news